By combining the agents ruxolitinib and ibrutinib, the hope is that not only will the response rate against chronic GVHD increase but also will the duration of involvement decrease by targeting GVHD from both the JAK and BTK pathways. This evidence concerns the gene BTK and graft versus host disease.